Vir Biotechnology Inc (VIR)

Currency in USD
8.39
-0.48(-5.41%)
Closed·
8.30-0.09(-1.05%)
·
VIR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.348.91
52 wk Range
5.4514.38
Key Statistics
Prev. Close
8.39
Open
8.77
Day's Range
8.34-8.91
52 wk Range
5.45-14.38
Volume
3.09M
Average Volume (3m)
2.44M
1-Year Change
47.7113%
Book Value / Share
5.30
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VIR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
23.13
Upside
+175.63%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Vir Biotechnology Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 23.13
(+175.63% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Morgan Stanley
Buy28.00+233.73%25.00MaintainNov 10, 2026
Needham
Buy20.00+138.38%18.00MaintainNov 05, 2026
H.C. Wainwright
Buy22.00+162.22%20.00MaintainOct 08, 2026
Raymond James
Buy19.00+126.46%-MaintainSep 28, 2026
H.C. Wainwright
Buy20.00+138.38%-MaintainAug 10, 2026

Vir Biotechnology Inc SWOT Analysis


Pipeline Promise
Vir Biotechnology's HDV treatment and T-cell engager oncology programs show potential for billion-dollar peak sales, driving investor interest
Financial Fortitude
Strong cash position funds operations into mid-2027, but negative EPS projections and cash burn rate pose challenges for long-term sustainability
Market Volatility
Stock performance fluctuates amid clinical progress and setbacks, with analysts setting price targets ranging from $14 to $31, reflecting mixed market sentiment
Strategic Crossroads
Vir's future hinges on HDV and TCE program success, balancing promising research with financial pressures in a competitive biotech landscape
Read full SWOT analysis

Vir Biotechnology Inc Earnings Call Summary for Q1/2026

  • VIR reported Q1 2026 EPS of -$0.85 vs. -$0.10 forecast, missing by 750%; revenue negative $29K vs. $55.89M expected, triggering 7.39% stock decline
  • Net loss widened to $125.7M from $121M YoY despite reduced R&D expenses of $108.9M (down 8.2%) and SG&A costs of $23.3M (down 2.5%)
  • Company secured Astellas collaboration to strengthen cash position, extending operational runway into second half of 2028 despite ongoing losses
  • Management projects continued EPS losses through 2027 while focusing on pipeline advancement and cost management amid rising clinical expenses
Last Updated: 2026-05-12, 10:34 a/m
Read Full Transcript

Earnings

Latest Release
Nov 04, 2026
EPS / Forecast
-0.57 / -0.74
Revenue / Forecast
-188K / 865.13K
EPS Revisions
Last 90 days

VIR Income Statement

Compare VIR to Peers and Sector

Metrics to compare
VIR
Peers
Sector
Relationship
P/E Ratio
−7.8x−1.3x−0.2x
PEG Ratio
−0.12−0.080.00
Price/Book
1.6x2.4x2.6x
Price / LTM Sales
4.7x5.6x2.6x
Upside (Analyst Target)
175.6%172.6%77.0%
Fair Value Upside
Unlock17.9%13.7%Unlock

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company’s preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
60.60M35.38%508.43M
Other Institutional Investors
94.79M55.35%795.33M
Public Companies & Retail Investors
15.88M9.27%133.21M
Total
171.27M100.00%1.44B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.13.11%22,448,921188,346
Vanguard Portfolio Management, LLC7.02%12,024,354100,884

People Also Watch

97.17
KOD
-0.75%
1.570
OPK
-2.48%
13.13
XP
-4.02%
4.210
PGEN
+1.20%
51.79
APPN
+1.61%

FAQ

What Is the Vir Biotech (VIR) Stock Price Today?

The Vir Biotech stock price today is 8.39 USD.

What Stock Exchange Does Vir Biotech Trade On?

Vir Biotech is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Vir Biotech?

The stock symbol for Vir Biotech is "VIR."

What Is the Vir Biotech Market Cap?

As of today, Vir Biotech market cap is 1.44B USD.

What Is Vir Biotech's Earnings Per Share (TTM)?

The Vir Biotech EPS (TTM) is -1.18.

When Is the Next Vir Biotech Earnings Date?

Vir Biotech will release its next earnings report on Feb 25, 2027.

From a Technical Analysis Perspective, Is VIR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Vir Biotech Stock Split?

Vir Biotech has split 0 times.

How Many Employees Does Vir Biotech Have?

Vir Biotech has 367 employees.

What is the current trading status of Vir Biotech (VIR)?

As of Nov 22, 2026, Vir Biotech (VIR) is trading at a price of 8.39 USD, with a previous close of 8.39 USD. The stock has fluctuated within a day range of 8.34 USD to 8.91 USD, while its 52-week range spans from 5.45 USD to 14.38 USD.

What Is Vir Biotech (VIR) Price Target According to Analysts?

The average 12-month price target for Vir Biotech is 23.13 USD, with a high estimate of 30 USD and a low estimate of 17 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +175.63% Upside potential.

What Is the VIR Premarket Price?

VIR's last pre-market stock price is 8.85 USD. The pre-market share volume is 3,680.00, and the stock has decreased by -0.02, or -0.23%.

What Is the VIR After Hours Price?

VIR's last after hours stock price is 8.30 USD, the stock has decreased by -0.09, or -1.05%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.